Latest News and Events
Filter by
Selections
December 2, 2025
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Read MoreDecember 1, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Read MoreNovember 24, 2025
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Read MoreNovember 18, 2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read MoreNovember 4, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Read MoreOctober 28, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 21, 2025